ATE457988T1 - A2a-adenosin-rezeptor-antagonisten - Google Patents

A2a-adenosin-rezeptor-antagonisten

Info

Publication number
ATE457988T1
ATE457988T1 AT07796492T AT07796492T ATE457988T1 AT E457988 T1 ATE457988 T1 AT E457988T1 AT 07796492 T AT07796492 T AT 07796492T AT 07796492 T AT07796492 T AT 07796492T AT E457988 T1 ATE457988 T1 AT E457988T1
Authority
AT
Austria
Prior art keywords
receptor antagonists
adenosine receptor
alkyl
compounds
cns diseases
Prior art date
Application number
AT07796492T
Other languages
English (en)
Inventor
Martin C Clasby
Samuel Chackalamannil
Andrew Stamford
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE457988T1 publication Critical patent/ATE457988T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT07796492T 2006-06-26 2007-06-25 A2a-adenosin-rezeptor-antagonisten ATE457988T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81651606P 2006-06-26 2006-06-26
PCT/US2007/014886 WO2008002596A2 (en) 2006-06-26 2007-06-25 Adenosine a2a receptor antagonists

Publications (1)

Publication Number Publication Date
ATE457988T1 true ATE457988T1 (de) 2010-03-15

Family

ID=38846284

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07796492T ATE457988T1 (de) 2006-06-26 2007-06-25 A2a-adenosin-rezeptor-antagonisten

Country Status (10)

Country Link
US (1) US7713985B2 (de)
EP (1) EP2038285B1 (de)
JP (1) JP2010509189A (de)
CN (1) CN101506215A (de)
AT (1) ATE457988T1 (de)
CA (1) CA2655987A1 (de)
DE (1) DE602007004851D1 (de)
ES (1) ES2339502T3 (de)
MX (1) MX2009000104A (de)
WO (1) WO2008002596A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009111449A1 (en) * 2008-03-04 2009-09-11 Schering Corporation 1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo [4,3-e] -1,2,4-triazolo [4,3-c] pyrimidin-3-one compounds for use as adenosine a2a receptor antagonists
JP5143898B2 (ja) * 2008-05-09 2013-02-13 パイオニア株式会社 空間映像表示装置
JP5765239B2 (ja) 2009-03-13 2015-08-19 アドヴィナス・セラピューティックス・リミテッド 置換縮合ピリミジン化合物
TWI548411B (zh) 2009-04-28 2016-09-11 Kyowa Hakko Kirin Co Ltd Exercise disorder treatment
WO2011060207A1 (en) 2009-11-16 2011-05-19 Schering Corporation FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY
WO2011101861A1 (en) 2010-01-29 2011-08-25 Msn Laboratories Limited Process for preparation of dpp-iv inhibitors
JP5843869B2 (ja) * 2010-09-24 2016-01-13 アドヴィナス・セラピューティックス・リミテッド アデノシン受容体拮抗薬としての縮合三環化合物
AU2013251079B2 (en) * 2012-04-20 2017-03-23 Ucb Pharma S.A. Methods for treating Parkinson's disease
CN102659620A (zh) * 2012-05-18 2012-09-12 东南大学 2,4-双(三氟甲基)苄肼的合成方法
WO2014101113A1 (en) * 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Piperazine-substituted 7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
CN105025899B (zh) * 2012-12-28 2017-08-18 默沙东公司 具有A2A拮抗剂性质的杂二环取代的‑[1,2,4]三唑并[1,5‑c]喹唑啉‑5‑胺化合物
WO2014101120A1 (en) 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
KR20210093964A (ko) 2018-11-20 2021-07-28 머크 샤프 앤드 돔 코포레이션 치환된 아미노 트리아졸로피리미딘 및 아미노 트리아졸로피라진 아데노신 수용체 길항제, 제약 조성물 및 그의 용도
EP3883576B1 (de) 2018-11-20 2025-12-17 Merck Sharp & Dohme LLC Substituierte aminotriazolopyrimidine und amino-triazolopyrazin-adenosinrezeptor-antagonisten, pharmazeutische zusammensetzungen und deren verwendung
KR102653800B1 (ko) 2018-11-30 2024-04-01 머크 샤프 앤드 돔 엘엘씨 아데노신 수용체 길항제로서의 9-치환된 아미노 트리아졸로 퀴나졸린 유도체, 제약 조성물 및 그의 용도
CA3120331A1 (en) 2018-11-30 2020-06-04 Merck Sharp & Dohme Corp. 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use
EP3935059B1 (de) 2019-03-05 2025-04-23 Centre For Addiction And Mental Health Modulatoren der ampa-rezeptor-signalisierung
AU2021241886A1 (en) 2020-03-26 2022-10-27 Nxera Pharma Uk Limited Triazolone compounds
JP7675094B2 (ja) 2020-03-26 2025-05-12 ネクセラ・ファーマ・ユーケイ・リミテッド トリアゾロン化合物
WO2021191376A1 (en) 2020-03-26 2021-09-30 Astrazeneca Ab Triazolone compounds
AU2021243725A1 (en) 2020-03-26 2022-10-27 Nxera Pharma Uk Limited 5-amino-8-(4-pyridyl)-(1,2,4)triazolo(4,3-c)pyrimidin-3-one compounds for use against cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955465A (en) * 1996-03-22 1999-09-21 Neurogen Corporation 1,2,4-triazolo 4,3-c!quinazolin-3-ones and 1,2,4-triazolo 4,3-c!quinazolin-3-thiones
WO2004058974A1 (en) * 2002-12-27 2004-07-15 Actar Ab A method of drug screening to select agonists or antagonists of g protein coupled receptors (gpcr).
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
CA2622741A1 (en) * 2005-09-19 2007-03-29 Schering Corporation 2-heteroaryl-pyrazolo-[4, 3-e]-1, 2, 4-triazolo-[1,5-c]-pyrimidine as adenosine a2a receptor antagonists

Also Published As

Publication number Publication date
WO2008002596A2 (en) 2008-01-03
EP2038285B1 (de) 2010-02-17
MX2009000104A (es) 2009-01-23
JP2010509189A (ja) 2010-03-25
ES2339502T3 (es) 2010-05-20
CA2655987A1 (en) 2008-01-03
US7713985B2 (en) 2010-05-11
EP2038285A2 (de) 2009-03-25
DE602007004851D1 (de) 2010-04-01
WO2008002596A3 (en) 2008-07-03
CN101506215A (zh) 2009-08-12
US20080255156A1 (en) 2008-10-16

Similar Documents

Publication Publication Date Title
ATE457988T1 (de) A2a-adenosin-rezeptor-antagonisten
TW200726765A (en) Triazolopyridine cannabinoid receptor 1 antagonists
TNSN07164A1 (en) Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists
MX340965B (es) Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular.
GEP20115174B (en) Triazolopyrazine derivatives useful as anti-cancer agents
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
IL176110A0 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
PH12012501122A1 (en) Pteridinones as inhibitors of polo-like kinase
MX2009004900A (es) Arilamidas sustituidas por tiazol u oxazol.
NO20084853L (no) Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni
MX2012004848A (es) Compuestos heterociclicos triciclicos.
MX2009009238A (es) Nuevos inhibidores de fosfodiesterasa.
PL1891029T3 (pl) Związki organiczne do leczenia stanów zapalnych lub alergicznych
UA92670C2 (ru) Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе
MX2010001020A (es) Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas.
MY169274A (en) Fused, tricyclic sulfonamide inhibitors of gamma secretase
MX2010002938A (es) Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.
MX2009011059A (es) Aminopirimidinas utiles como inhibidores de cinasas.
MA28706B1 (fr) Antagoniste des recepteurs du glucagon, preparation et utilisations therapeutiques
DE602007001463D1 (de) Pyrimidin-, chinazolin-, pteridin- und triazinderivate
TW200637863A (en) Organic compounds
ATE446089T1 (de) 2-benzoyl-imidazopyridin-derivate, herstellungsverfahren und ihre verwendung für therapeutika
MX2007013624A (es) Inhibidores de proteina cinasa.
TW200716547A (en) Piperidin-4-yl-amide derivatives
TW200630366A (en) Organic compounds

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties